Antiplatelet drugs - Open Access .click

Results 191 to 200 of about 51,164 (250)

Efficacy and Safety of Subcutaneous Efgartigimod PH20 in Adults With Primary Immune Thrombocytopenia (ADVANCE SC): A Multicenter, Randomized, Double‐Blinded, Placebo‐Controlled, Phase 3 Trial

American Journal of Hematology, Volume 101, Issue 7, Page 1494-1506, July 2026.
ABSTRACT Primary autoimmune thrombocytopenia (ITP) is characterized by thrombocytopenia, bleeding, and reduced health‐related quality of life. In the Phase 3 ADVANCE IV study, intravenous efgartigimod induced significant platelet count responses versus placebo in patients with chronic ITP. ADVANCE SC, a Phase 3, multicenter, randomized, double‐blinded,
Nichola Cooper +546 more
wiley +1 more source

Population Pharmacokinetics of Ticagrelor during Veno‐Arterial ECMO in Acute Coronary Syndrome: Model‐Informed Dosing Simulations

Clinical Pharmacology &Therapeutics, Volume 120, Issue 1, Page 193-202, July 2026.
Although patients with acute coronary syndrome supported by veno‐arterial extracorporeal membrane oxygenation (VA‐ECMO) have a high risk of thrombosis and bleeding, antiplatelet pharmacology in this setting is not well defined. This prospective observational study investigated the population pharmacokinetics of ticagrelor and its active metabolite AR ...
Soyoung Kang +9 more
wiley +1 more source

Associations of GA and GMI/GA Ratio With All‐Cause Mortality in Well‐Controlled Type 2 Diabetes Defined by Continuous Glucose Monitoring

Diabetes/Metabolism Research and Reviews, Volume 42, Issue 5, July 2026.
ABSTRACT Aims There is uncertainty whether traditional glycemic metrics remain associated with long‐term outcomes among patients with type 2 diabetes who achieve recommended continuous glucose monitoring (CGM) targets. This study was aimed to investigate the association of glycated albumin (GA) and ratio of glucose management indicator to GA (GMI/GA ...
Jiaying Ni +9 more
wiley +1 more source

Therapeutic Potential of Berberis vulgaris in Modulating Metabolic Syndrome Biomarkers: Mechanistic Insights and Functional Food Implications

Food Frontiers, Volume 7, Issue 4, July 2026.
ABSTRACT Barberry (Berberis vulgaris) has emerged as a promising functional food candidate for the management of metabolic syndrome due to its diverse bioactive constituents, particularly berberine. This review synthesizes current experimental and clinical evidence regarding its effects on glycemic control, lipid metabolism, blood pressure regulation ...
Fakhar Shahid +5 more
wiley +1 more source

First Revision of the Guidelines for the Diagnosis and Management of Remethylation Disorders

Journal of Inherited Metabolic Disease, Volume 49, Issue 4, July 2026.
ABSTRACT This guideline summarizes diagnostic and therapeutic approaches based on a systematic literature review and evidence evaluation using the GRADE methodology. Given the limited high‐quality data, expert consensus was additionally obtained through a modified Delphi process.
Giorgia Olivieri +26 more
wiley +1 more source

Ischemia–Reperfusion Injury: Molecular Mechanisms and Therapeutic Interventions

MedComm, Volume 7, Issue 7, July 2026.
Multiorgan ischemia–reperfusion injury begins with ischemia‐induced ATP depletion and ionic imbalance, followed by reperfusion‐triggered mitochondrial ROS/RNS bursts, regulated cell death, and DAMP release. Sterile inflammation converges on endothelial–immune–coagulation crosstalk, where NETs drive immunothrombosis, no‐reflow, and remote organ injury ...
Peng An +4 more
wiley +1 more source

Discontinuation of SGLT2i After a Urogenital Infection: A Population‐Based Matched Cohort Study of Patients With Type 2 Diabetes

Diabetes, Obesity and Metabolism, Volume 28, Issue 7, Page 5740-5750, July 2026.
ABSTRACT Aims Sodium‐glucose cotransporter 2 inhibitors (SGLT2is) improve glycaemic control and cardiorenal outcomes in Type 2 diabetes, particularly in patients at elevated cardiovascular and kidney risk, yet discontinuation following infections appears common.
Christine Ljungberg +5 more
wiley +1 more source

GLP‐1 Receptor Agonist Therapy and Cardiorenal Outcomes in Type 1 Diabetes: A Propensity‐Matched Real‐World Analysis

Diabetes, Obesity and Metabolism, Volume 28, Issue 7, Page 6347-6357, July 2026.
ABSTRACT Aims Evidence on cardiovascular/renal outcomes associated with GLP‐1‐based therapies in type 1 diabetes (T1D) is limited. We examined the effects of GLP‐1‐based therapy on major clinical outcomes and safety, including diabetic ketoacidosis (DKA) and hypoglycemia risk, in adults with T1D in a large real‐world cohort.
Anastasios Tentolouris +7 more
wiley +1 more source

In Vitro Biological Activities of Piper corcovadensis C.DC.: Antioxidant, Antineoplastic‐Related and Antibacterial Effects

The FASEB Journal, Volume 40, Issue 11, 15 June 2026.
Piper corcovadensis extract is rich in bioactive compounds with antioxidant potential, capable of decreasing ROS levels; antitumor activity in cutaneous melanoma cells SK‐MEL‐28; and anti‐inflammatory activity, decreasing the expression of IL‐6 and NLPR3 genes and increasing TNF expression, without cytotoxicity to healthy peripheral blood cells (PBMCs).
Bruno Henrique Fontoura +7 more
wiley +1 more source

humans
platelet aggregation inhibitors
3. good health

aspirin
clopidogrel
blood platelets

thrombosis
ticlopidine
dipyridamole